window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Therapeutic Areas

  • Opinion & Events,Research & Development,Therapeutic Areas

    Halving fertility treatment costs could more than double ART births, study finds

    Reducing patient out-of-pocket fertility treatment costs by half could increase [...]

    July 7, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    ReproNovo doses first participant in Phase 2 embryo implantation trial

    ReproNovo has dosed the first participant in a European Phase [...]

    July 6, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Novartis agrees $1.5bn Myricx Bio acquisition to strengthen ADC pipeline

    Novartis has agreed to acquire UK biotech Myricx Bio for [...]

    July 6, 2026
  • Medical devices,Therapeutic Areas

    Active Care Group to develop specialist rehabilitation hospital in Stoke Mandeville

    Active Care Group has announced plans to develop a new [...]

    July 3, 2026
  • Digital & Data,Research & Development,Therapeutic Areas

    Fleming Initiative selects AWS to support global antimicrobial resistance platform

    The Fleming Initiative has selected Amazon Web Services (AWS) to [...]

    July 3, 2026
  • Digital & Data,Research & Development,Therapeutic Areas

    Study supports home-based EEG platform for Alzheimer’s clinical trials

    A peer-reviewed study has demonstrated that Cumulus Neuroscience’s NeuLogiq platform [...]

    July 3, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Inocras and AimedBio partner on whole genome sequencing for ADC trials

    Inocras and AimedBio have formed a strategic partnership to integrate [...]

    July 2, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Inaqovi combination wins EU approval for AML treatment

    Otsuka Pharmaceutical Europe has received an amended European Commission marketing [...]

    July 2, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Grifols doses first patient in Phase 3 alpha-1 therapy trial

    Grifols has dosed the first participant in a Phase 3 [...]

    July 2, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Elixirgen signs worldwide option deal with Nippon Shinyaku for Duchenne therapy

    Elixirgen Therapeutics has signed an option agreement with Nippon Shinyaku [...]

    June 29, 2026
Previous91011Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • FDA approves Tivicay PD for children with HIV weighing at least 2kg
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Tezspire meets Phase 3 endpoints in eosinophilic esophagitis
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Brenntag signs Eastern Europe nutraceutical distribution deal
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top